CCChoi-Fong Cho

Choi-Fong Cho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Choi-Fong Cho has a total of 112 co-authors. Here are the top co-authors by number of shared publications:

  • Sean E. Lawler

    Department of Pathology and Laboratory Medicine, Legorreta Cancer Center, Brown University, Providence, RI 02903, USA

    5 shared publications
  • E. Antonio Chiocca

    Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

    4 shared publications
  • Sean E. Lawler

    Department of Pathology and Laboratory Medicine, Legorreta Cancer Center, Brown University, Providence, RI 02903, United States

    4 shared publications
  • Bradley L. Pentelute

    Department of Chemistry Massachusetts Institute of Technology Cambridge MA 02139 United States

    3 shared publications
  • Colin M. Fadzen

    Department of Chemistry Massachusetts Institute of Technology Cambridge MA 02139 United States

    3 shared publications
  • Justin M. Wolfe

    Department of Chemistry Massachusetts Institute of Technology Cambridge MA 02139 United States

    3 shared publications

Latest Publications

  • Open Access

    Modulation of blood-tumor barrier transcriptional programs improves intratumoral drug delivery and potentiates chemotherapy in GBM

    by Jorge L. Jimenez-Macias, Philippa Vaughn-Beaucaire, Ayush Bharati, Zheyun Xu, Megan Forrest, Jason Hong, Michael Sun, Andrea Schmidt, Jasmine Clark, William Hawkins, et al.

    Efficient drug delivery to glioblastoma (GBM) is a major obstacle as the blood-brain barrier (BBB) and the blood-tumor barrier (BTB) prevent passage of the majority of chemotherapies into the brain. Here, we identified a transcriptional 12-gene signature associated with the BTB in GBM. We identified CDH5 as a core molecule in this set and confirmed its expression in GBM vasculature using transcriptomics and immunostaining of patient specimens. The indirubin-derivative, 6-bromoindirubin acetoxime (BIA), down-regulates CDH5 and other BTB signature genes, causing endothelial barrier disruption in vitro and in murine GBM xenograft models. Treatment with BIA increased intratumoral cisplatin accumulation and potentiated DNA damage by targeting DNA repair pathways. Last, using an injectable BIA nanoparticle formulation, PPRX-1701, we significantly improved cisplatin efficacy in murine GBM. Our work reveals potential targets of the BTB and the bifunctional properties of BIA as a BTB modulator and a potentiator of chemotherapy, supporting its further development.


  • Open Access

    High-throughput glioblastoma-neurovascular assembloids model blood-tumor barrier disruption, tumor reprogramming and therapeutic efficacy

    by Pei Zhuang, Shuai Gao, Benjamin Scott, Yi-Bo Jia, Wei-Min Meng, Rui Yin, Xin-Yu Nie, Soniya Tamhankar, Sean P. Palecek, Ludovica Gaiaschi, et al.

    The blood-tumor barrier (BTB) in glioblastoma is an abnormal neurovascular interface that can be focally leaky yet still restrict effective therapy. We present a rapid human BTB model in which patient-derived glioblastoma stem cells (GSCs), human brain endothelial cells, pericytes and astrocytes self-assemble within 72 hours into uniform three-dimensional “BTB assembloids”. Thousands can be generated in parallel in standard plates, enabling high-throughput studies and drug testing. These assembloids establish spatial glioma-vascular and glioma-astrocyte niches with focal loss of endothelial tight-junction proteins, astrocyte recruitment and endothelial recruitment toward tumor clusters with localized junctional disruption at the tumor-vascular interface. BTB-conditioned GSCs acquire more invasive, stemness, mesenchymal and angiogenic programs compared with matched GSC neurospheres, and these BTB-conditioned states translate into greater engraftment and infiltrative growth in vivo, accompanied by vascular remodeling and BTB-like barrier disruption. The assembloid platform supports quantitative, ‘barrier-aware’ assessment of compound access and retention in human BTB- (and BBB)-like contexts, revealing that functional P-glycoprotein efflux persists despite increased BTB permeability, thereby dissociating structural barrier leakiness from therapeutic accessibility. It is modular and compatible with iPSC-derived brain cells (for example brain endothelial cells), microglia or other immune components, thereby providing a route toward genotype- and immunity-specific modeling. Together, this establishes BTB assembloids as a scalable human system to interrogate glioblastoma-neurovascular crosstalk and to evaluate brain-tumor therapeutics.


  • Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood–brain barrier in rodents and primates

    by Yizheng Yao, Jun Wang, Yi Liu, Yuan Qu, Kaikai Wang, Yang Zhang, Yuxin Chang, Zhi Yang, Jie Wan, Junfeng Liu, et al.

    The development of gene therapies for the treatment of diseases of the central nervous system has been hindered by the limited availability of adeno-associated viruses (AAVs) that efficiently traverse the blood–brain barrier (BBB). Here, we report the rational design of AAV9 variants displaying cell-penetrating peptides on the viral capsid and the identification of two variants, AAV.CPP.16 and AAV.CPP.21, with improved transduction efficiencies of cells of the central nervous system on systemic delivery (6- to 249-fold across 4 mouse strains and 5-fold in cynomolgus macaques, with respect to the AAV9 parent vector). We also show that the neurotropism of AAV.CPP.16 is retained in young and adult macaques, that this variant displays enhanced transcytosis at the BBB as well as increased efficiency of cellular transduction relative to AAV9, and that it can be used to deliver antitumour payloads in a mouse model of glioblastoma. AAV capsids that can efficiently penetrate the BBB will facilitate the clinical translation of gene therapies aimed at the central nervous system.


  • Open Access

    A Tumor-Homing Peptide Platform Enhances Drug Solubility, Improves Blood–Brain Barrier Permeability and Targets Glioblastoma

    by Choi-Fong Cho, Charlotte E. Farquhar, Colin M. Fadzen, Benjamin Scott, Pei Zhuang, Niklas von Spreckelsen, Andrei Loas, Nina Hartrampf, Bradley L. Pentelute, Sean E. Lawler

    Background: Glioblastoma (GBM) is the most common and deadliest malignant primary brain tumor, contributing significant morbidity and mortality among patients. As current standard-of-care demonstrates limited success, the development of new efficacious GBM therapeutics is urgently needed. Major challenges in advancing GBM chemotherapy include poor bioavailability, lack of tumor selectivity leading to undesired side effects, poor permeability across the blood–brain barrier (BBB), and extensive intratumoral heterogeneity. Methods: We have previously identified a small, soluble peptide (BTP-7) that is able to cross the BBB and target the human GBM extracellular matrix (ECM). Here, we covalently attached BTP-7 to an insoluble anti-cancer drug, camptothecin (CPT). Results: We demonstrate that conjugation of BTP-7 to CPT improves drug solubility in aqueous solution, retains drug efficacy against patient-derived GBM stem cells (GSC), enhances BBB permeability, and enables therapeutic targeting to intracranial GBM, leading to higher toxicity in GBM cells compared to normal brain tissues, and ultimately prolongs survival in mice bearing intracranial patient-derived GBM xenograft. Conclusion: BTP-7 is a new modality that opens the door to possibilities for GBM-targeted therapeutic approaches.


  • Targeting Glioblastoma Using a Novel Peptide Specific to a Deglycosylated Isoform of Brevican

    by Niklas von Spreckelsen, Colin M. Fadzen, Nina Hartrampf, Yarah Ghotmi, Justin M. Wolfe, Shipra Dubey, Bo Yeun Yang, Marie F. Kijewski, Shuyan Wang, Charlotte Farquhar, et al.

    Glioblastoma (GBM) is the most common and deadliest form of brain tumor and remains amongst the most difficult cancers to treat. Brevican (Bcan), a central nervous system (CNS)‐specific extracellular matrix protein, is upregulated in high‐grade glioma cells, including GBM. A Bcan isoform lacking most glycosylation, dg‐Bcan, is found only in GBM tissues. Here, dg‐Bcan is explored as a molecular target for GBM. In this study, a d‐peptide library is screened to identify a small 8‐amino acid dg‐Bcan‐Targeting Peptide (BTP) candidate, called BTP‐7 that binds dg‐Bcan with high affinity and specificity. BTP‐7 is preferentially internalized by dg‐Bcan‐expressing patient‐derived GBM cells. To demonstrate GBM targeting, BTP‐7 is radiolabeled with 18F, a radioisotope of fluorine, and increased radiotracer accumulation is found in intracranial GBM established in mice using positron emission tomography (PET) imaging. dg‐Bcan is an attractive molecular target for GBM, and BTP‐7 represents a promising lead candidate for further development into novel imaging agents and targeted therapeutics.


  • Open Access

    BTP-7, a novel peptide for therapeutic targeting of malignant brain tumors

    by Niklas von Spreckelsen, Yarah Ghotmi, Colin M. Fadzen, Justin M. Wolfe, Nina Hartrampf, Charlotte Farquhar, Sonja Bergmann, Mykola Zdioruk, J. Roscoe Wasserburg, Emily Murrell, et al.

    Background: Targeted therapies for malignant brain cancer that are currently available have little clinical activity, highlighting an urgent need for the development of novel precision medicines. Brevican (Bcan), a central nervous system (CNS)-specific extracellular matrix protein is upregulated in glioma cells. A brevican isoform lacking glycosylation, dg-Bcan, is a unique glioma marker and thus represents a valuable target for anti-cancer therapy. In this study, we aimed to find a versatile dg-Bcan specific ligand to facilitate glioma targeting. Methods: We screened a D-peptide library to identify dg- B can- T argeting P eptide (BTP) candidates, which were characterized extensively through binding kinetic analyses, cell uptake tests and animal studies. Results: The top candidate, BTP-7 binds dg-Bcan with high affinity and specificity, is preferentially internalized by Bcan-expressing glioma cells and can cross the blood-brain barrier in vitro and in mice. Functionalization of camptothecin with BTP-7 led to increased drug delivery to intracranial glioblastoma and cytotoxicity in tumor tissues, as well as prolonged survival in tumor-bearing mice. Conclusion: dg-Bcan is an attractive therapeutic target for high-grade gliomas, and BTP-7 represents a promising lead candidate for further development into novel targeted therapeutics. Key points: BTP-7 is a high affinity peptide ligand for the dg-Bcan protein and Bcan-expressing cells. BTP-7 targets human intracranial GBM xenografts in mice. Functionalization of a toxic anti-cancer drug with BTP-7 enables targeted delivery of the therapeutic to intracranial GBM in mice Importance of the Study: Targeted therapies for malignant brain cancer that are currently available have little clinical activity, highlighting an urgent need for the development of novel precision medicines that can selectively recognize and kill high-grade glioma tissues. A protein called dg-Bcan is an ideal target because it is present only in the extracellular matrix of high-grade glioma cells and is absent from normal brain tissues. Here, we describe the discovery of a novel dg- B can- T argeting P eptide, called BTP-7 that can bind specifically to high-grade glioma cells/tissues, and thus serve as a promising drug delivery vehicle.

  • Blood–brain-barrier organoids for investigating the permeability of CNS therapeutics

    by Sonja Bergmann, Sean E. Lawler, Yuan Qu, Colin M. Fadzen, Justin M. Wolfe, Michael S. Regan, Bradley L. Pentelute, Nathalie Y. R. Agar, Choi-Fong Cho

    In vitro models of the blood–brain barrier (BBB) are critical tools for the study of BBB transport and the development of drugs that can reach the CNS. Brain endothelial cells grown in culture are often used to model the BBB; however, it is challenging to maintain reproducible BBB properties and function. ‘BBB organoids’ are obtained following coculture of endothelial cells, pericytes and astrocytes under low-adhesion conditions. These organoids reproduce many features of the BBB, including the expression of tight junctions, molecular transporters and drug efflux pumps, and hence can be used to model drug transport across the BBB. This protocol provides a comprehensive description of the techniques required to culture and maintain BBB organoids. We also describe two separate detection approaches that can be used to analyze drug penetration into the organoids: confocal fluorescence microscopy and mass spectrometry imaging. Using our protocol, BBB organoids can be established within 2–3 d. An additional day is required to analyze drug permeability. The BBB organoid platform represents an accurate, versatile and cost-effective in vitro tool. It can easily be scaled to a high-throughput format, offering a tool for BBB modeling that could accelerate therapeutic discovery for the treatment of various neuropathologies.


  • Open Access

    Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents

    by Choi-Fong Cho, Justin M. Wolfe, Colin M. Fadzen, David Calligaris, Kalvis Hornburg, E. Antonio Chiocca, Nathalie Y. R. Agar, Bradley L. Pentelute, Sean E. Lawler

    Culture-based blood–brain barrier (BBB) models are crucial tools to enable rapid screening of brain-penetrating drugs. However, reproducibility ofin vitrobarrier properties and permeability remain as major challenges. Here, we report that self-assembling multicellular BBB spheroids display reproducible BBB features and functions. The spheroid core is comprised mainly of astrocytes, while brain endothelial cells and pericytes encase the surface, acting as a barrier that regulates transport of molecules. The spheroid surface exhibits high expression of tight junction proteins, VEGF-dependent permeability, efflux pump activity and receptor-mediated transcytosis of angiopep-2. In contrast, the transwell co-culture system displays comparatively low levels of BBB regulatory proteins, and is unable to discriminate between the transport of angiopep-2 and a control peptide. Finally, we have utilized the BBB spheroids to screen and identify BBB-penetrant cell-penetrating peptides (CPPs). This robustin vitroBBB model could serve as a valuable next-generation platform for expediting the development of CNS therapeutics.


  • PS2 - 178 Brevican-Specific Peptides for the Development of Next-Generation Targeted Theranostics for High Grade Gliomas

    by C.F. Cho, K. Kasai, J. Wolfe, K. Hornburg, F. Bononi, L. Luyt, B. Pentelute, M. Viapiano, E.A. Chiocca, S. Lawler

    High-grade gliomas are deadly cancers, and current standard-of-care has demonstrated limited success. The ability to specifically target glioma cells can allow for the development of improved theranostic agents leading to better detection methods, as well as safer anti-cancer therapies. Brevican (Bcan), a CNS-specific protein is upregulated in glioma cells and correlates with tumor progression. Particularly, a Bcan isoform lacking normal glycosylation, called B/bDg is a unique glioma marker and is not expressed in non-cancerous tissues. Therefore, B/bDg represents a valuable target for anti-cancer strategies. We describe here the discovery of novel high-affinity B/bDg-targeted peptides using rapid combinatorial library screening approaches and a microfluidic sorting device of our own design. Briefly, a one-bead-one-compound (OBOC) peptide library was screened against small magnetic particles decorated with B/bDg. Positive “hit” beads labeled with magnetic particles were isolated using an inexpensive but yet, accurate and high-throughput in-house microfluidic magnetic-activated sorter. These hits were exposed to cells expressing B/bDg, and beads with the highest cell association were isolated and sequenced. Seven novel peptides were identified. Cell uptake analyses and blocking studies revealed that 5 of these peptides displayed specific uptake in B/bDg-overexpressing cells. These candidates displayed nano-/micromolar binding affinity for recombinant B/bDg protein. Further analyses of these candidates using confocal microscopy revealed increased peptide binding/uptake in patient-derived glioma stem cells (GSCs) compared with primary human astrocytes. We plan to incorporate these onto multi-functional BBB-penetrating nanoparticles loaded with imaging agents or a drug payload to translate them into highly selective and efficacious brain cancer theranostic agents.

  • Design of a Microfluidic Chip for Magnetic-Activated Sorting of One-Bead-One-Compound Libraries

    by Choi-Fong Cho, Kyungheon Lee, Maria-Carmela Speranza, Fernanda C. Bononi, Mariano S. Viapiano, Leonard G. Luyt, Ralph Weissleder, E. Antonio Chiocca, Hakho Lee, Sean E. Lawler

    Molecular targeting using ligands specific to disease markers has shown great promise for early detection and directed therapy. Bead-based combinatorial libraries have served as powerful tools for the discovery of novel targeting agents. Screening platforms employing magnetic capture have been used to achieve rapid and efficient identification of high-affinity ligands from one-bead-one-compound (OBOC) libraries. Traditional manual methodologies to isolate magnetized “hit” beads are tedious and lack accuracy, and existing instruments to expedite bead sorting tend to be costly and complex. Here, we describe the design and construction of a simple and inexpensive microfluidic magnetic sorting device using standard photolithography and soft lithography approaches to facilitate high-throughput isolation of magnetized positive hit beads from combinatorial libraries. We have demonstrated that the device is able to sort magnetized beads with superior accuracy compared to conventional manual sorting approaches. This chip offers a very convenient yet inexpensive alternative for screening OBOC libraries.